Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Depo-Provera

(medroxyprogesterone)

ApprovedSmall molecule

This medication is a hormone injection used to prevent pregnancy by stopping the release of eggs from the ovaries and thickening the uterine lining. It is also used to treat endometriosis, a painful condition where tissue similar to the uterine lining grows in other areas of the body.[2] Depo-Provera is currently approved and in use across 9 indications[4].[1]

Depo-Provera is one of 317 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.

9

Indications

16

Total Trials

0

Active Trials

316

Competitors

4

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Kidney CancerActive, not recruiting

AdenocarcinomaActive, not recruiting

AtherosclerosisActive, not recruiting

CognitionActive, not recruiting

Venous MalformationActive, not recruiting

Breast CancerActive, not recruiting

Endometrial CancerActive, not recruiting

Hot FlashesActive, not recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Kidney CancerPhase 3

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

AtherosclerosisPhase 3

Active, not recruiting

CognitionPreclinical

Active, not recruiting

Venous MalformationApproved

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Endometrial CancerPhase 2

Active, not recruiting

Hot FlashesPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Depo-Provera

Tecentriq

Trodelvy

Tykerb

Halaven

Adriamycin

GGynecologic Oncology Group

Avastin

BBio-Thera Solutions

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Prolia

Gemzar

GGynecologic Oncology Group

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atherosclerosis2 trials

Estrogen and Graft Atherosclerosis Research Trial (EAGER)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000605

Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000559

Breast Cancer2 trials

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

Completed·SSWOG Cancer Research Network·Phase 3·NCT00002920·313 enrolled

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00026286

Endometrial Cancer2 trials

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00033358·52 enrolled

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

Terminated·GGynecologic Oncology Group·Phase 2·NCT00003179·360 enrolled

Hot flashes1 trial

Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00030914·227 enrolled

Systemic Lupus Erythematosus1 trial

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00006133·970 enrolled

8 more indications

Cognition1 trial

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

Completed·UUniversity of Colorado, Denver·N/A·NCT02122198·17 enrolled

Alzheimer's Disease1 trial

Alzheimer's Disease: Therapeutic Potential of Estrogen

Completed·UUniversity of Wisconsin, Madison·Phase 2/3·NCT00066157·42 enrolled

Kidney Cancer1 trial

Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Completed·CCentre Leon Berard·Phase 3·NCT00416429·456 enrolled

Estrogen Replacement Therapy1 trial

Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss

Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 3·NCT00004650·150 enrolled

Venous malformation1 trial

Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation

Unknown status·HHaEmek Medical Center, Israel·Phase 4·NCT05491343·28 enrolled

Polycystic Ovarian Syndrome1 trial

Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)

Completed·YYale University·N/A·NCT00743574·36 enrolled

Adenocarcinoma1 trial

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Completed·GGynecologic Oncology Group·Phase 2·NCT00064025·75 enrolled

Estrogen1 trial

Postmenopausal Estrogen/Progestin Interventions (PEPI)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000466

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DEPO-PROVERA

NDA NDA012541

Jan 1, 1982

PROVERA

NDA NDA011839

Oct 29, 1992

DEPO-PROVERA

NDA NDA020246

Dec 17, 2004

DEPO-SUBQ PROVERA 104

NDA NDA021583

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for medroxyprogesterone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Depo-Provera drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — medroxyprogesterone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for medroxyprogesterone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021583). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Related News